SCHEMBL4050475

SCHEMBL4050475

Cc1cccc(-c2nc3ncc(-c4ccccc4)cc3[nH]2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 1/20 0.52
AURKA O14965 6/20 0.52
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
PTGES O14684 1/20 0.47
PIN1 Q13526 1/20 0.47
KIT P10721 1/20 0.45
NPBWR1 P48145 1/20 0.44
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
USP30 Q70CQ3 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059131 0.87 AURKA (0.56) AURKANPC1RAB9AKITNOS3
SCHEMBL4054183 0.85 SCD (0.56) NR1I3AURKANPC1RAB9APTGES
SCHEMBL4061906 0.84 MGAM (0.51) AURKAPIN1CYP3A4GUSBMAPK14
SCHEMBL4060428 0.84 AURKA (0.66) AURKAKITNOS3NOS1NOS2
SCHEMBL4052742 0.83 GUSB (0.52) AURKAPTGESPIN1KITNPBWR1
SCHEMBL4054040 0.83 AURKA (0.60) NR1I3AURKANPC1RAB9APTGES
SCHEMBL4055330 0.83 AURKA (0.67) NR1I3AURKANPC1RAB9APIN1
SCHEMBL4060508 0.82 PTGES (0.45) NR1I3AURKANPC1RAB9APTGES
SCHEMBL4058315 0.82 AURKA (0.52) AURKANOS3NOS1NOS2USP30
SCHEMBL4059595 0.82 TP53 (0.56) NR1I3AURKANPC1RAB9ANOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NR1I3 3378/4885AURKA 247/4885NPC1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.